NCT02550535 - A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Myelodysplastic Syndromes (MDS)Acute Myeloid Leukaemia (AML)

Interventions

GENETIC

Autologous WT1 TCR transduced T cells

Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion

Trial Locations (6)

AZ St Jan Brugge-Oostende AV, Bruges

UZ Leuven, Leuven

Uniklinikum Dresden, Dresden

University Hospitals Bristol NHS Foundation Trust, Bristol

The Leeds Teaching Hospitals NHS Trust, Leeds

University College London Hospitals NHS Trust, London